Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Accounts Payables (2020 - 2026)

Aura Biosciences filings provide 7 years of Accounts Payables readings, the most recent being $2.6 million for Q1 2026.

  • Quarterly Accounts Payables rose 28.27% to $2.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Mar 2026, up 28.27% year-over-year, with the annual reading at $1.5 million for FY2025, 32.77% down from the prior year.
  • Accounts Payables hit $2.6 million in Q1 2026 for Aura Biosciences, up from $1.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.9 million in Q4 2022 and bottomed at $553000.0 in Q2 2023.
  • Average Accounts Payables over 5 years is $1.7 million, with a median of $1.8 million recorded in 2023.
  • The largest annual shift saw Accounts Payables plummeted 53.84% in 2023 before it surged 163.83% in 2024.
  • Aura Biosciences' Accounts Payables stood at $2.9 million in 2022, then crashed by 38.82% to $1.8 million in 2023, then grew by 28.93% to $2.3 million in 2024, then crashed by 32.77% to $1.5 million in 2025, then surged by 66.11% to $2.6 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Accounts Payables are $2.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025).